Bruno Massidda

Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patients

R. Labianca, L. Frontini, V. Zagonel, 2017, British Journal of Cancer.

Doxorubicin-Docetaxel Sequential Schedule: Results of Front-Line Treatment in Advanced Breast Cancer

G. Failla, G. Gasparini, M. Fanelli, 2002, Oncology.

Cancer patients as `experts' in defining quality of life domains. A multicentre survey by the Italian Group for the Evaluation of Outcomes in Oncology (IGEO)

R. Gareri, M. Costantini, P. Casali, 2000, Quality of Life Research.

Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patients

R. Labianca, L. Frontini, V. Zagonel, 2017, British Journal of Cancer.

Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: The Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study

R. Biamonte, M. Valerio, J. Brüning, 2006, BMC Cancer.